Marchex, Inc. (MCHX)
NASDAQ: MCHX · Real-Time Price · USD
2.080
-0.050 (-2.35%)
Aug 6, 2025, 4:00 PM - Market closed
Verve Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 47.95 | 48.12 | 49.91 | 52.17 | 53.48 | 51.22 | Upgrade | |
Revenue Growth (YoY) | -2.67% | -3.58% | -4.33% | -2.44% | 4.41% | -6.00% | Upgrade |
Cost of Revenue | 16.95 | 17.17 | 20.58 | 20.46 | 21.69 | 20.89 | Upgrade |
Gross Profit | 31 | 30.95 | 29.33 | 31.71 | 31.78 | 30.33 | Upgrade |
Selling, General & Admin | 23.72 | 22.38 | 21.62 | 23.3 | 22.84 | 29.45 | Upgrade |
Research & Development | 11.84 | 12.41 | 15.36 | 14.36 | 16.11 | 21 | Upgrade |
Operating Expenses | 36.01 | 35.4 | 38.96 | 39.78 | 43.44 | 55.78 | Upgrade |
Operating Income | -5.01 | -4.45 | -9.63 | -8.08 | -11.65 | -25.45 | Upgrade |
Interest Expense | -0.05 | -0.12 | -0.17 | - | -0.04 | -0.03 | Upgrade |
Interest & Investment Income | - | - | - | 0.1 | 0 | 0.14 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | -0.01 | 2.49 | 0.02 | Upgrade |
EBT Excluding Unusual Items | -5.05 | -4.57 | -9.8 | -7.99 | -9.2 | -25.33 | Upgrade |
Merger & Restructuring Charges | - | - | -0.01 | -0.07 | -0.14 | 1.04 | Upgrade |
Impairment of Goodwill | - | - | - | - | - | -14.69 | Upgrade |
Asset Writedown | - | - | - | - | - | -4.96 | Upgrade |
Other Unusual Items | - | - | - | - | 5.19 | - | Upgrade |
Pretax Income | -5.05 | -4.57 | -9.82 | -8.06 | -4.16 | -43.94 | Upgrade |
Income Tax Expense | 0.43 | 0.38 | 0.09 | 0.18 | 0.23 | -1.92 | Upgrade |
Earnings From Continuing Operations | -5.48 | -4.95 | -9.91 | -8.25 | -4.39 | -42.02 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | 3.57 | Upgrade |
Net Income | -5.48 | -4.95 | -9.91 | -8.25 | -4.39 | -38.45 | Upgrade |
Net Income to Common | -5.48 | -4.95 | -9.91 | -8.25 | -4.39 | -38.45 | Upgrade |
Shares Outstanding (Basic) | 43 | 43 | 43 | 43 | 44 | 46 | Upgrade |
Shares Outstanding (Diluted) | 43 | 43 | 43 | 43 | 44 | 46 | Upgrade |
Shares Change (YoY) | 1.32% | 1.26% | -1.39% | -1.58% | -5.07% | 1.76% | Upgrade |
EPS (Basic) | -0.13 | -0.11 | -0.23 | -0.19 | -0.10 | -0.83 | Upgrade |
EPS (Diluted) | -0.13 | -0.11 | -0.23 | -0.19 | -0.10 | -0.83 | Upgrade |
Free Cash Flow | -1.67 | -1.53 | -5.77 | -5.16 | -7.69 | -4.73 | Upgrade |
Free Cash Flow Per Share | -0.04 | -0.04 | -0.14 | -0.12 | -0.17 | -0.10 | Upgrade |
Gross Margin | 64.66% | 64.32% | 58.76% | 60.78% | 59.43% | 59.22% | Upgrade |
Operating Margin | -10.44% | -9.24% | -19.30% | -15.48% | -21.79% | -49.70% | Upgrade |
Profit Margin | -11.43% | -10.28% | -19.86% | -15.80% | -8.21% | -75.06% | Upgrade |
Free Cash Flow Margin | -3.49% | -3.19% | -11.56% | -9.88% | -14.39% | -9.23% | Upgrade |
EBITDA | -2.2 | -1.8 | -5.76 | -4.04 | -5.68 | -18.21 | Upgrade |
EBITDA Margin | -4.59% | -3.74% | -11.54% | -7.75% | -10.63% | -35.55% | Upgrade |
D&A For EBITDA | 2.81 | 2.65 | 3.87 | 4.03 | 5.97 | 7.25 | Upgrade |
EBIT | -5.01 | -4.45 | -9.63 | -8.08 | -11.65 | -25.45 | Upgrade |
EBIT Margin | -10.44% | -9.24% | -19.30% | -15.48% | -21.79% | -49.70% | Upgrade |
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.